Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Genprex Inc (GNPX)
Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Genprex (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications....

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor...

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) Phase 2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase...

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”)...

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) to Present at BIO-Europe 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general...

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”);...

GNPX : 4.55 (+5.76%)
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 4.55 (+5.76%)
Genprex (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical...

GNPX : 4.55 (+5.76%)
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 4.55 (+5.76%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 4.55 (+5.76%)
RHHBY : 32.9200 (+0.58%)
JAZZ : 119.33 (+0.36%)
ALXO : 15.11 (+3.00%)
ACHL : 1.3300 (+0.76%)

Barchart Exclusives

3 Unusually Active Call Options to Buy Now for the Long Haul
There were 774 unusually active call options in Thursday’s trading, with plenty of names worth considering as long-term investments. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar